Introduction {#s1}
============

Whilst obesity contributes to diabetes and hypertension, both leading causes of progressive chronic kidney disease (CKD), data suggests that obesity is an independent risk factor for CKD ([@B1]). Diabetes and obesity related CKD appear to share the same initial pathophysiology ([@B1]). Increasing BMI leads to renal hyperfiltration and proteinuria that eventually culminates in hypofiltration and CKD. Diabetic nephropathy (DN) occurs in approximately one third of cases of diabetes (both type 1 and type 2) and is the most common cause of CKD and end stage renal failure ([@B2]). DN is mediated by transforming growth factor-β1 (TGF-β1) and TGF-β1 promoted fibrosis is induced by increasing the number of local fibroblasts, which are the effecter cells in the production and accumulation of the extracellular matrix. Epithelial-to-mesenchymal transition (EMT) is increasingly recognized as a key component in this process by promoting the transition of resident renal epithelial cells to a fibroblast phenotype ([@B3]). Recently, multiple studies have implicated microRNAs in this process. MicroRNAs are small, endogenous RNAs that regulate gene expression by silencing the translation of mRNA. The microRNAs miR 192 and the miR 200 family contribute to kidney fibrosis by suppressing EMT, targeting zinc E-box binding homeobox 1 and 2 (ZEB1 and ZEB2) that encode for transcriptional repressors for E-cadherin, essential for maintaining the epithelial phenotype ([@B4]--[@B6]). This leads to an increase in collagen deposition in the extracellular matrix and the thickening of the glomerular basement, a common feature of DN.

Weight loss in the clinically obese patient, including that achieved surgically, leads to an improvement in renal function ([@B7]--[@B9]). Bariatric or metabolic surgery encompasses several gastrointestinal surgical procedures that offer metabolic modulation to diminish metabolic dysfunction and induce substantial weight loss through the BRAVE physiological steps--bile flow alteration, reduction of gastric size, anatomical gut rearrangement, and altered flow of nutrients, vagal manipulation, and enteric gut hormone modulation ([@B10]). The two most common bariatric procedures worldwide are the Roux-en-Y gastric bypass (RYGB) and the sleeve gastrectomy ([@B11]). In a RYGB, a small gastric pouch (15--30mL) is created and separated from the larger stomach remnant. The jejunum is then incised from the duodenum and anastomized to the small stomach pouch forming a distinctive "Y" shape that gives this procedure its name ([@B12]). In a sleeve gastrectomy, a longitudinal gastric sleeve is created running from the esophagus to the small intestine that is separated from the larger excised stomach ([@B13]). In comparison to non-surgical strategies, bariatric surgery is more effective at achieving sustained weight loss, improved quality of life and increased life expectancy ([@B14], [@B15]). Several studies have shown that bariatric surgery also leads to remission or resolution of type 2 diabetes and improved glycaemic control ([@B16]--[@B19]). These improvements are observed early post-operatively, before substantial weight loss and to a greater extent than in patients who achieve similar weight loss non-surgically, and are therefore, thought to offer weight-independent metabolic effects ([@B20], [@B21]) in addition to weight-dependent metabolic actions. Hypothesizes for this phenomenon include the foregut, hindgut, and midgut theories ([@B22]), but the precise mechanisms behind improvement of diabetes following bariatric surgery are still not fully understood. Bariatric surgery also leads to improvements in cancer risk, sleep apnoea, and other obesity-associated disorders ([@B23], [@B24]). Thus, bariatric surgery may target and improve renal function through direct mechanisms of weight loss as well as through diabetes dependent mechanisms.

MicroRNAs have attracted a great amount of recent attention as potential novel biomarkers of disease due to their stability in biofluids and their facile detection through PCR and profiling platforms ([@B25], [@B26]). Circulating microRNAs are reported biomarkers for cancer, obesity, and diabetes ([@B25], [@B27], [@B28]), and distinct bariatric microRNA profiles have been characterized in circulation ([@B28], [@B29]). Urinary microRNAs are reported biomarkers for immunoglobulin A nephropathy and bladder cancer ([@B30], [@B31]). Currently the non-invasive diagnosis of CKD relies on urinary microalbuminuria and estimated glomerular filtration rate (eGFR). However, the sensitivity and specificity of these markers are poor, particularly in obese patients, and only manifest late in the disease process.

We hypothesized that bariatric surgery modulates the urinary levels of microRNAs involved in the regulation of renal function. Therefore, we aimed to study urinary expression of renal microRNAs in bariatric patients before and after surgery in comparison to non-surgical control subjects.

Materials and Methods {#s2}
=====================

Study Design
------------

Urine samples were collected for 10 healthy weight controls, seven morbidly obese controls and 24 bariatric surgical patients in Hull and East Yorkshire Hospitals and Imperial College Healthcare NHS Trusts under ethics approvals 09/H1304/46 and 08/H0711/123. Informed written consent was provided by all participants enrolled in this study and all appropriate guidelines were followed when conducting the methods. For the bariatric cohort, urine samples were obtained pre-operatively and at two periods post-operatively--between 2 and 6 months and between 1 and 2 years ([Table 1](#T1){ref-type="table"}). Nine out of the 24 bariatric patients had diabetes pre-operatively. Bariatric surgery was performed laparoscopically. Twenty bariatric patients had a RYGB and four had a sleeve gastrectomy. All bariatric patients fulfilled NICE qualifying criteria for bariatric surgery ([@B32]). All subjects had normal serum urea, creatinine, and eGFRs at baseline.

###### 

Study summary.

                   **Controls**   **Bariatric cohort**                             
  ---------------- -------------- ---------------------- ------------- ----------- -------------
  *n*              10             7                      24            20          4
  Age              39.1 (16.3)    54 (11.7)              45.7 (10.8)   45 (10.4)   49.1 (13.7)
  Female (*n*)     8              3                      16            14          2
  Diabetes (*n*)   0              1                      9             8           1

*Values represent mean. Standard deviation in parenthesis*.

Urinary RNA Extraction
----------------------

RNA was extracted from 250 μl of urine using the *mir*Vana PARIS kit (Ambion, Paisley, UK) according to the manufacturer\'s instructions with the one modification; to normalize and for carrier purposes, 30 femtomoles of synthetic *C. elegans* miR-39 (Ambion) was spiked into the urine samples prior to the acid-phenol:chloroform phase. Cel. miR-39 was chosen as carrier as it lacks sequence homology with human miRNAs. RNA was eluted in 100 μl nuclease free water.

Cell Culture
------------

The human kidney proximal tubule cell (PTC) line HK-2 was obtained from ATCC (LGC Standards, Teddington, UK) and maintained in DMEM/Ham\'s F12, supplemented with 10% v/v fetal bovine serum (FBS), 1% Penicillin/Streptomycin antibiotics (100 U/ml, 100 μg/ml, respectively), and 1% Insulin-Transferrin-Sodium Selenite (Sigma-Aldrich, Gillingham, UK) as previously described ([@B6]).

Transfections
-------------

Endogenous microRNA levels were manipulated in HK-2 cells through the transfection of microRNA miR 192 mimic, a gain-of-function experiment designed to determine the biological activity of miR 192. mIRIDIAN microRNA mimics and mimic controls were purchased from Dharmacon (Lafayette, CO, USA). The siPORT NeoFX transfection agent was used according to the manufacturer\'s instructions. HK-2 cells at approximately 80% confluence were trypsinized and seeded at 50,000 cells per well in complete media in 24 well cell culture plates and transfected with miR-192 mimic at 10, 20, and 50 nM concentrations for 48 h. Following SiPORT transfection RNA was extracted from HK-2 cells using the *mir*VANA PARIS kit according to manufacturer\'s instructions and eluted in 75 μl nuclease free water.

Quantitative PCR
----------------

MicroRNA was reverse transcribed into cDNA using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems, Paisley, UK) and messenger RNA (mRNA) was reverse transcribed using the High Capacity Reverse Transcription kit (Applied Biosystems) according to manufacturer\'s instructions. Relative microRNAs and mRNA levels were determined by real time, quantitative PCR using TaqMan Fast Universal Master Mix (Applied Biosystems). Quantitative PCR was performed in triplicate on the Applied Biosystems 7,500 Fast System. All PCR and RT probes were obtained from Applied Biosystems. Urinary microRNA expression was first normalized to creatinine to correct for diuretic effect (Creatinine Assay, R & D Systems, Abingdon, UK) and then normalized to cel. miR-39. Cellular microRNA expression following HK-2 transfections was normalized to U6 small nuclear RNA and mRNA expression was normalized to GAPDH, a frequently used housekeeping gene. Relative expression was calculated using the 2^−ΔCt^ method ([@B33]).

Statistical Analysis
--------------------

Urinary microRNA data is expressed as fold change relative to pre-operative levels or morbidly obese control levels. Data is represented as mean ± standard error of mean (SEM). Statistical significance was determined using ANOVA (with a post-test for linear trend) and paired/unpaired Student\'s *t*-test where appropriate. Significance was considered as *p* \< 0.05. Statistical analysis was performed using GraphPad Prism 6.0 (Graphpad, La Jolla, CA, USA).

Results {#s3}
=======

Bariatric Clinical Outcomes
---------------------------

Bariatric surgery induced substantial clinical improvements in all bariatric patients ([Figure 1](#F1){ref-type="fig"}). Reduction in BMI was significant within 100 days of surgery and mean BMI decreased by almost 30% at 100 days or more after surgery. Mean levels of fasting blood glucose also decreased following bariatric surgery, decreasing from 7.5 mmol/L pre-operatively to 5.6 mmol/L 100 days or more following surgery, although this decrease was not statistically significant. eGFR following bariatric surgery was unchanged (mean 74--79 mL/min).

![Clinical measurements. Pre-operative, post-operative, and control levels of **(A)** BMI, **(B)** fasting blood glucose levels and **(C)** eGFR. Data represent mean ± SEM. ^\*^*p* \< 0.05, ^\*\*\*\*^*p* \< 0.0001 by Student\'s *t*-test.](fendo-10-00319-g0001){#F1}

Bariatric Surgery Increases Urinary miR 192 Levels
--------------------------------------------------

We initially assessed the urinary expression of miR 192, a consistently abundant renal microRNA ([@B34]). In patients who had laparoscopic RYGB, levels of miR 192 significantly increased 1.3 and 2.9-fold (relative to pre-operative levels) at 2--6 months and 1--2 years, respectively, following surgery ([Figure 2A](#F2){ref-type="fig"}). A similar increase was observed in sleeve gastrectomy patients. MiR 192 levels increased 1.3-fold at 2--6 months following sleeve procedures and 4.7-fold (significant relative to pre-operative levels) at 1--2 years post-operatively ([Figure 2B](#F2){ref-type="fig"}). Increase in urinary miR 192 levels was consistent when patients were stratified by pre-operative diabetes status. In patients with diabetes urinary levels of miR 192 increased 1.5-fold at 2--6 months and significantly 3.6-fold at 1--2 years following bariatric surgery ([Figure 2C](#F2){ref-type="fig"}). Patients without diabetes demonstrated a significant 2.8-fold increase in miR 192 levels at 1--2 years following surgery ([Figure 2D](#F2){ref-type="fig"}).

![Urinary miR 192 expression following bariatric surgery. **(A)** RYGB patients. **(B)** Sleeve gastrectomy patients. **(C)** Patients with diabetes. **(D)** Patients without diabetes. Data represents mean fold change ± SEM relative to mean preoperative expression. *n* = 20 for RYGB, *n* = 4 for sleeve, *n* = 9 for diabetes, and *n* = 15 for individuals without diabetes. Each patient is represented by a unique symbol. ^\*^*p* \< 0.05 vs. preoperative expression by paired *t*-test.](fendo-10-00319-g0002){#F2}

When expressed as fold change relative to the morbidly obese control group, bariatric pre-operative miR 192 levels were lower (0.6-fold), potentially reflecting the higher BMI in patients undergoing bariatric surgery ([Figure 3A](#F3){ref-type="fig"}). Bariatric miR 192 expression was slightly higher 2--6 months following surgery (0.8-fold relative to morbidly obese controls). However, 1--2 years following bariatric surgery, mean miR 192 level was nearly 2-fold higher relative to the morbidly obese cohort and was comparable to miR 192 levels in those with a healthy weight (BMI under 25, [Figure 3A](#F3){ref-type="fig"}). Although comparative two-way fold changes were not significant, the linear trend with time was (*p* = 0.0117, one-way ANOVA). An inverse correlation between miR 192-fold change and change in BMI post-operatively was also significant (*p* = 0.0342, Pearson\'s correlation, [Figure 3B](#F3){ref-type="fig"}). The data show that bariatric surgery shifts urinary miR 192 expressions from levels observed in a morbidly obese population to levels observed in a healthy weight population.

![Bariatric urinary miR 192 expression relative to a morbidly obese cohort. **(A)** Bariatric and healthy weight miR 192 expression relative to a morbidly obese control group. Data represents mean ± SEM relative to mean preoperative expression. Morbidly obese is a BMI ≥ 40 kg/m^2^, healthy weight is a BMI \< 25 kg/m^2^. *n* = 7 for morbidly obese, *n* = 10 healthy weight, *n* = 24 for preoperatively, 2--6 months and 1--2 years post-operatively. **(B)** Pearson correlation of miR 192-fold change against change in post-operative BMI. *n* = 46. **(C)** Timecourse of miR 192 expression following surgery. Data represented as fold change relative to individual preoperative expression for 24 bariatric patients.](fendo-10-00319-g0003){#F3}

Of the 24 individuals who made up the bariatric cohort, 20 had increased urinary miR 192 expression post-operatively relative to their pre-operative levels, including 16 out of the 20 RYGB patients, eight out of nine patients with diabetes and all four sleeve gastrectomy patients. A timecourse of post-operative miR 192 expressions in RYGB and sleeve patients relative to their individual pre-operative miR 192 levels can be found in [Figure 3C](#F3){ref-type="fig"}. A significant correlation was found between individual, personalized fold changed in miR 192 levels and days following surgery (*p* = 0.0051, Pearson\'s correlation). This illustrated a trend of a gradual, general increase in miR 192 levels in urine which is enhanced and sustained with time and consistent with migration toward the healthy weight control phenotype.

Bariatric Surgery Increases Urinary Levels of miR 200a and miR 200b
-------------------------------------------------------------------

Urinary levels of miR 200a and miR 200b were also measured. Both are expressed in the kidney and change in their expression is associated with diabetic nephropathy ([@B5], [@B6]). MiR 200a urine levels increased 2.5-fold at 2--6 months and 3.4-fold at 1--2 years following surgery ([Figure 4A](#F4){ref-type="fig"}), although neither increase achieved statistical significance. MiR 200b levels increased 5.8-fold at 2--6 months and strikingly 28.6-fold (significantly different from the pre-surgery levels) at 1--2 years post-operatively ([Figure 4B](#F4){ref-type="fig"}). All but one patient demonstrated a post-operative increase of urinary miR 200a and all patients demonstrated an increase in urinary miR 200b relative to their individual pre-operative level. Significant correlations were observed between both miR 200a and miR 200b and days following bariatric surgery ([Figures 4C,D](#F4){ref-type="fig"}, *p* = 0.0071 and 0.044, respectively, Pearson\'s correlation). There were also significant correlations between urinary levels of miR 192 and both miR 200a and miR 200b ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}, *p* = 0.0364 and *p* \< 0.0001, respectively, Pearson\'s correlation).

![Urinary expression of miR 200 following bariatric surgery. **(A)** miR-200a, *n* = 9 **(B)** miR-200b, *n* = 8. Data represents mean fold change ± SEM relative to mean preoperative expression. ^\*\*^*p* \< 0.01 vs. preoperative expression by paired *t*-test. Each patient is represented by a unique symbol. Timecourse of **(C)** miR 200a and **(D)** miR 200b expression following surgery. Data represented as fold change relative to individual preoperative expression.](fendo-10-00319-g0004){#F4}

Mechanistic Studies in the Human PTC Line, HK-2
-----------------------------------------------

To explore the mechanistic implications of altered microRNA expression following bariatric surgery, we used the human PTC HK-2 renal cell line to examine changes in phenotype. Transfection with all three concentrations of miR 192 mimic increased miR 192 expression 4,000, 16,000, and 18,000-fold, respectively, relative to cells transfected with a scrambled control ([Figure 5A](#F5){ref-type="fig"}). Transfection of miR 192 increased levels of miR 200 at all concentrations, although the increase was only significant at 10 nM ([Figure 5B](#F5){ref-type="fig"}). Expression levels of ZEB1 and Colα1 were unaltered for all three miR 192 mimic concentrations ([Figures 5C,E](#F5){ref-type="fig"}). However, transfection with 50 nM miR 192 mimic concentration resulted in a significant 0.6-fold decrease in ZEB2 ([Figure 5D](#F5){ref-type="fig"}).

![miR 192 mimic transfection of HK2 cells illustrates its anti-fibrotic role. Expression of **(A)** miR 192 **(B)** miR 200a **(C)** ZEB1 **(D)** ZEB2 and **(E)** Colα1 following 48 h of 10, 20, and 50 nM miR 192 mimic transfection. Data represents mean ± SEM relative to transfection with a scrambled control. ^\*^*p* \< 0.05, ^\*\*\*^*p* \< 0.001, ^\*\*\*\*^*p* \< 0.0001, *n* = 3.](fendo-10-00319-g0005){#F5}

Discussion {#s4}
==========

There is a growing body of evidence that biofluid miRNA expression can be indicative of disease progression and prognosis ([@B35]--[@B37]). Urinary expression of microRNAs has also been proposed as useful in the diagnosis and prognosis of renal disease ([@B38]). We therefore considered whether bariatric surgery modulates urinary levels of miRNAs that regulate kidney function.

Three kidney-expressed microRNAs, miR 192, miR 200a, and miR 200b, were shown to be upregulated in urine following bariatric surgery, an increase that was consistent across surgical type and diabetes status and was sustained and enhanced with time. Bariatric surgery shifts urinary miR 192 expression from levels seen in morbidly obese patients to levels comparable with those seen in a healthy cohort. In mechanistic studies, the transfection of miR 192 in a human kidney PTC cell line increased miR 200a and decreased ZEB2, a key transcriptional promoter of kidney fibrosis. These three microRNAs assessed in urine could potentially represent non-invasive, anti-fibrotic biomarkers for surgery-induced improvement in renal function.

The kidney-specific deletion of Dicer, a ribonuclease involved in microRNA biogenesis, leads to proteinuria, glomerular disease, and tubular injury in mice ([@B39]--[@B41]). This illustrates the important functional roles of microRNAs in kidney pathophysiology. MiR 192 is one of 5 microRNAs whose expression is higher in the kidney relative to other organs ([@B34]), and its levels are reduced in human renal biopsies from patients with advanced diabetic nephropathy, levels that correlate with tubulointerstitial fibrosis, and decreased GFR, reflecting miR 192\'s key anti-fibrotic role ([@B6]). *In vitro* incubation of PTCs with TGF-β1 decreases miR 192 expression and the overexpression of miR 192 suppresses ZEB1 and ZEB2, decreasing TGF-β1 mediated E-cadherin suppression ([@B6]). In diabetic apoE mice, miR 192 expression was downregulated in the kidney and treatment of PTCs with TGF-β1 results in a reduction of miR 192 ([@B42]). Renal levels of the miR 200 family are decreased in mouse models of renal scarring and by TGF-β1 in rat PTCs ([@B43]). Injection of miR 200b precursor antagonizes ZEB1/ZEB2 induction, decreases collagen synthesis, and ameliorates fibrosis ([@B44]). p53 tumor suppressor increases expression of miR 192 and miR 200, suppressing EMT ([@B45]). It has also been reported that miR 200 expression is a strong biomarker for epithelial vs. mesenchymal phenotype in cancer ([@B46]). MiR 200 overexpression results in mesenchymal to epithelial transition in mouse carcinomas and overexpressing miR 200 *in vitro* increases E-cadherin and represses EMT ([@B4], [@B5]). Here, miR 192 transfection of human PTCs led to an increase in miR 200a, indicating that miR 192 could act upstream to miR 200 in a hierarchical regulation pathway, suggesting miR 192 may be a master microRNA regulator in the kidney ([Figure 6](#F6){ref-type="fig"}). Previously miR 192 has been shown to upregulate miR 200b/c expression in mesangial cells ([@B47]).

![The renal function of miR 192 and miR 200. (**Left**) Mechanism for glucose-mediated renal fibrosis in the proximal tubular cells. Diabetes increases TGF-β which inhibits miR 192/200, lifting the suppression on ZEB and EMT. (**Right**) Suggested mechanism following bariatric surgery.](fendo-10-00319-g0006){#F6}

In contrast to their roles in PTCs, miR 192, and miR 200 appear to have pro-fibrotic effect in mesangial cells. TGF-β1 increases miR 192 in mouse mesangial cells and repression of ZEB1/ZEB2 expression by miR 192 leads to collagen synthesis ([@B48]). The inhibition of miR 192 in streptozotin-induced diabetic mice reduces proteinuria ([@B49]). In mesangial cells, miR 200 family represses ZEB1/ZEB2, promoting fibrosis ([@B47]). The pleiotropic, cell-specific roles miR 192 and miR 200 play in renal fibrosis reflect the complex physiology of the kidney. Indeed, the renal cortex and the medulla have different microRNA expression profiles ([@B50]). It is worth noting that proximal tubular cells are further along the urinary tract than mesangial cells of the glomerulas and that urinary levels of miR 192 and miR 200 are decreased in patients with bladder cancer, correlating with increased EMT ([@B31]).

In this study patients had normal renal function and therefore a change in renal function following surgery was not expected. However, other studies have reported improvements in renal function following bariatric procedures. Weight loss is associated with a reduction in proteinuria, including weight loss achieved surgically ([@B7]--[@B9]). Bariatric surgery improves renal function in patients with pre-existing glomerular hyperfiltration ([@B9]). Surgery also leads to reduced levels of albuminuria 1 year post-operatively, and levels continue to decrease up to 2 years and were maintained up to 5 years post-surgery ([@B51], [@B52]). Remission of microalbuminuria in individuals with diabetes can reach 60% 5 years following surgery. Surgery also has preventive effects, reducing the incidence of microalbuminuria by 80% and diabetic nephropathy by 60% compared to patients treated medically ([@B52]). Bariatric surgery can also lead to improvement and remission in patients with established CKD ([@B53]). The results presented here suggest miR 192 may mediate these renal improvements following bariatric surgery.

The early detection of DN is important in preventing progression to renal failure and there are considerable limitations of conventional markers of kidney function. Novel markers of DN have been reported, including proteins, peptides, and growth factors ([@B54]). Several studies have reported distinct microRNA profiles in urine, urinary sediments, and circulation in cases of kidney diseases. Urinary miR 29b, miR 29c, and miR 93 levels are correlated with proteinuria and renal scarring in patients with IgA nephropathy ([@B55]). Urinary microRNA profiles can also be used to differentiate various stages of diabetic nephropathy in individuals with type 1 diabetes ([@B35]). MicroRNA 145 is upregulated in the urinary exosomes of type 1 diabetes patients with microalbuminuria ([@B56]) and urinary microRNA levels, including levels of miR 192, can predict the development of microalbuminuria ([@B57]). In circulation, increased levels of miR 25, miR 27, miR 152, and miR 182 has been reported in patients with type 1 diabetes ([@B58]), and a recent report identified 10 elevated and two lowered microRNAs in patients with diabetes with DN relative to healthy controls ([@B59]). Circulating microRNAs can select diabetes patients with DN from those with good renal function, suggesting prognostic potential ([@B59]). This has led to interest in microRNAs as potential novel drug targets. The successful manipulation of miR 192 expression in the renal cortex of normal and diabetic mice ([@B60]) suggests the same may be possible in humans.

Other microRNAs have been reported to be involved in DN, including miR 21, miR 25, and miR 29 ([@B61]--[@B63]). The expression of more microRNAs needs to be assessed in bariatric urine samples and validated *in vitro*. However, there are limitations to using *in vitro* models of renal function, as EMT is more commonly observed in immortalized cell lines than *in vivo* renal fibrosis ([@B64]). The role of microRNAs in mediating the post-bariatric improvements in renal health needs to be confirmed in larger, prospective, multi-centre studies of bariatric patients including cohorts with varying degrees of kidney dysfunction.

In summary, bariatric surgery increased the urinary expression of the anti-fibrotic microRNAs miR 192 and miR 200 to levels found in the healthy controls. Several recent studies have assessed the suitability of urinary microRNAs as biomarkers, given the clinical ease of collecting and analyzing samples and the limitation of conventional markers of renal function. This study highlights the potential of urinary microRNAs as non-invasive biomarkers of health following bariatric surgery.
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Pearson correlation between the delta Ct of miR 192 and the delta Ct of **(A)** miR 200a and **(B)** miR 200b. *n* = 27 for miR 192 v miR 200a. *n* = 24 for miR 192 v miR 200b.
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Click here for additional data file.
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